Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.52 |
| ▸ | TP53 | P04637 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HTR1F | P30939 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30909012 | 1.00 | MAPT (0.52) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL6949289 | 0.89 | MAPT (0.51) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL30909109 | 0.89 | MAPT (0.51) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL6960878 | 0.85 | MAPT (0.57) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL30908855 | 0.85 | MAPT (0.57) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL30908989 | 0.84 | MAPT (0.57) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL6958342 | 0.84 | MAPT (0.57) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL6953187 | 0.83 | MAPT (0.58) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL30909221 | 0.81 | HTR1F (0.43) | MAPTTP53SMN1; SMN2THRBPOLB | |
| SCHEMBL6962292 | 0.81 | HTR1F (0.43) | MAPTTP53SMN1; SMN2THRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| EP-0929299-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA(b)BENZOFURANS | LILLY CO ELI (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-0929299-A4 | SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA(b)BENZOFURANS | LILLY CO ELI (US) | 2000-12-20 | — | — | EP | disclosed |
| US-5935992-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-08-10 | — | — | US | disclosed |
| US-5932739-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0929299-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA(b)BENZOFURANS | ELI LILLY AND COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5846995-A | Substituted 1, 2, 3, 4-tetrahydro-2-dibenzofuranamines and 2-amino-cyclohepta (6, 7-B) Benzofurans | ELI LILLY AND COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998008502-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b]BENZOFURANS | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | MAPT 3544/4885TP53 676/4885SMN1; SMN2 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.